Congress Scientific Watch

From World GI 2022:
Research sheds light on the immunogenicity of microsatellite instability-high or mismatch repair-deficient colorectal cancer with concomitant BRAF V600E or RAS mutations

From World GI 2022:
Tucatinib plus trastuzumab regimen has achieved “clinically meaningful” activity in previously treated patients with HER2-positive metastatic colorectal cancer

From World GI 2022:
Frailty, as assessed by a novel scoring system, is associated with worse short-term outcomes after oesophagectomy for oesophageal cancer in patients aged 65 years and older

From World GI 2022:
TOPAZ-1 exploratory analysis suggests that adding durvalumab to gemcitabine plus cisplatin improves advanced biliary tract cancer outcomes irrespective of the primary tumour site

From World GI 2022:
The presence of a BRCAness mutation in advanced biliary tract cancer may be a positive prognostic marker for response to platinum-based chemotherapy

From World GI 2022:
A novel second-generation CTLA4-inhibitor plus PD-1 inhibitor combination has achieved objective responses in patients with microsatellite stable, metastatic colorectal cancer

From ASCO 2022 Annual Meeting:
Preliminary findings indicate that patients with tumours harbouring NRG1 fusions may benefit from treatment with zenocutuzumab or seribantumab

From ASCO 2022 Annual Meeting:
Phase II results suggest trastuzumab deruxtecan may offer a novel treatment option for patients with HER2-expressing advanced biliary tract cancer

From ASCO 2022 Annual Meeting:
Combining first-line triplet therapy and lenalidomide maintenance with autologous stem-cell transplantation significantly improves multiple myeloma progression-free survival

From ASCO 2022 Annual Meeting:
Ifosfamide achieved better survival outcomes than topotecan plus cyclophosphamide among rEECur trial participants with recurrent or primary refractory Ewing sarcoma

From ASCO 2022 Annual Meeting:
Amivantamab shows activity in NSCLC patients with a primary MET exon 14 skipping mutation and when used in combination with lazertinib for those with EGFR mutations who have progressed after osimertinib and chemotherapy

From ESMO Breast Cancer 2022:
For patients with hormone receptor-positive, HER2-negative advanced breast cancer, the addition of ribociclib to fulvestrant continues to significantly improves overall survival after more than 70 months